Artificial intelligence in drug discovery: recent advances and future perspectives

Искусственный интеллект в разработке лекарственных средств: последние достижения и перспективы
José Jiménez-Luna, Francesca Grisoni, Gisbert Schneider, Nils Weskamp
2021-03-29

artificial intelligencechemical synthesis predictionde novo molecular designdeep learningmessage-passing models
Introduction: Artificial intelligence (AI) has inspired computer-aided drug discovery. The widespread adoption of machine learning, in particular deep learning, in multiple scientific disciplines, and the advances in computing hardware and software, among other factors, continue to fuel this development. Much of the initial skepticism regarding applications of AI in pharmaceutical discovery has started to vanish, consequently benefitting medicinal chemistry.Areas covered: The current status of AI in chemoinformatics is reviewed. The topics discussed herein include quantitative structure-activity/property relationship and structure-based modeling, de novo molecular design, and chemical synthesis prediction. Advantages and limitations of current deep learning applications are highlighted, together with a perspective on next-generation AI for drug discovery.Expert opinion: Deep learning-based approaches have only begun to address some fundamental problems in drug discovery. Certain methodological advances, such as message-passing models, spatial-symmetry-preserving networks, hybrid de novo design, and other innovative machine learning paradigms, will likely become commonplace and help address some of the most challenging questions. Open data sharing and model development will play a central role in the advancement of drug discovery with AI.
1
AI adoption in computer-aided drug discovery is accelerating due to advances in deep learning, computing hardware, and software.
2
Current AI applications in chemoinformatics address quantitative structure–activity/property prediction, structure-based modeling, de novo molecular design, and synthesis prediction.
3
Deep learning has begun addressing fundamental drug-discovery problems, but important methodological and practical limitations remain.
4
Message-passing models, spatial-symmetry-preserving networks, and hybrid de novo design are identified as promising next-generation approaches.
5
Open data sharing and collaborative model development are expected to be central to further progress in AI-driven drug discovery.

AI-based drug discovery and chemoinformatics applications

The current capabilities, limitations, and future methodological advances of artificial intelligence—particularly deep learning—for molecular property/activity prediction, structure-based modeling, de novo molecular design, and chemical synthesis prediction

Publication Details
Publication Date
2021-03-29
Journal
Publisher
ISSN
Cited by
488
Access Type
Author Information
Authors
José Jiménez-Luna
Francesca Grisoni
Gisbert Schneider
Nils Weskamp
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%